Education
About Us
Working with TipRanks
Follow Us
Argenx Se (ARGX)
NASDAQ:ARGX
ARGX Stock Chart & Stats
$748.72
$8.96(1.38%)
At close: 4:00 PM EST
$748.72
$8.96(1.38%)
Day’s Range― - ―
52-Week Range$510.06 - $934.62
Previous CloseN/A
Volume151.62K
Average Volume (3M)350.00K
Market Cap
$46.40B
Enterprise Value$42.91B
Total Cash (Recent Filing)$4.44B
Total Debt (Recent Filing)$83.49M
Price to Earnings (P/E)35.5
Beta0.24
Next Earnings
May 07, 2026EPS Estimate
5.72Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)8.02
Shares Outstanding61,883,408
10 Day Avg. Volume333,197
30 Day Avg. Volume350,004
Financial Highlights & Ratios
PEG Ratio0.77
Price to Book (P/B)7.04
Price to Sales (P/S)12.38
P/FCF Ratio61.05
Enterprise Value/Market Cap0.92
Enterprise Value/Revenue12.79
Enterprise Value/Gross Profit14.38
Enterprise Value/Ebitda32.93
Forecast
1Y Price Target
$1,039.72Price Target Upside38.87% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
EPS Forecast (FY)27.16
Revenue Forecast (FY)$5.91B
Bulls Say, Bears Say
Bulls Say
Commercial Momentum And Payer AccessStrong prescriber adoption, leadership in new biologic treatment starts, and favorable payer contracts point to sustained commercial traction that can drive ongoing sales growth.
Label Expansion PotentialRegulatory approval for Vyvgart in ocular and antibody‑negative myasthenia gravis would widen the eligible patient population and enable earlier prescribing by physicians, supporting higher market penetration.
Pipeline And Lifecycle DiversificationAdvancement of next‑generation FcRn candidates, an autoinjector device, and other early‑stage programs could create new revenue streams and strengthen competitive differentiation over time.
Bears Say
Market Skepticism And Relative UnderperformanceShares trading below peer biotech performance indicate investor skepticism about valuation and may exert downward pressure on the stock despite favorable clinical and commercial updates.
Pipeline SetbackDiscontinuation of an amyotrophic lateral sclerosis development program after an unsuccessful Phase IIa readout reduces near‑term pipeline breadth and eliminates a potential future product opportunity.
Pricing And Seasonality PressuresSeasonal demand patterns for injectable therapies combined with net pricing pressures could temporarily flatten revenue growth and constrain margin improvement.
Argenx Se News
ARGX FAQ
What was Argenx Se’s price range in the past 12 months?
Argenx Se lowest stock price was $510.06 and its highest was $934.62 in the past 12 months.
What is Argenx Se’s market cap?
Argenx Se’s market cap is $46.40B.
When is Argenx Se’s upcoming earnings report date?
Argenx Se’s upcoming earnings report date is May 07, 2026 which is in 63 days.
How were Argenx Se’s earnings last quarter?
Argenx Se released its earnings results on Feb 26, 2026. The company reported $8.02 earnings per share for the quarter, beating the consensus estimate of $5.948 by $2.072.
Is Argenx Se overvalued?
According to Wall Street analysts Argenx Se’s price is currently Undervalued.
Does Argenx Se pay dividends?
Argenx Se does not currently pay dividends.
What is Argenx Se’s EPS estimate?
Argenx Se’s EPS estimate is 5.72.
How many shares outstanding does Argenx Se have?
Argenx Se has 61,883,408 shares outstanding.
What happened to Argenx Se’s price movement after its last earnings report?
Argenx Se reported an EPS of $8.02 in its last earnings report, beating expectations of $5.948. Following the earnings report the stock price went down -5.56%.
Which hedge fund is a major shareholder of Argenx Se?
Currently, no hedge funds are holding shares in ARGX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Argenx Se Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$1,039.72 (38.87% Upside)
$1,039.72 (38.87% Upside)
Blogger Sentiment
Bullish
ARGX Sentiment 67%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 212.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.4%
Last 30 Days ▲ 13.1%
Last 30 Days ▲ 13.1%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.14%
12-Months-Change
Fundamentals
Return on Equity
20.17%
Trailing 12-Months
Asset Growth
39.99%
Trailing 12-Months
Company Description
Argenx Se
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis. The company is developing ARGX-213 targets FcRn; ARGX-121 and ARGX-220 targets immune system; ARGX-109 targets IL-6; ARGX-118 for inflammation; and ARGX-109, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It owns VYVGART; VYVGART HYTRULO; VYVDURA; ARGENX; ABDEG; NHANCE; SIMPLE ANTIBODY; and ARGENXMEDHUB. The company has strategic partnership with AbbVie S.À.R.L., Zai Lab Limited, and LEO Pharma A/S; and collaboration and license agreement with Genor Biopharma Co. Ltd, Université Catholique de Louvain, Sopartec S.A., NYU Langone Health, Leiden University Medical Center, AgomAb Therapeutics NV, Broteio Pharma B.V., VIB vzw, University of Texas, BioWa, Inc., and Shire International GmbH. It has collaboration agreement with Genmab A/S to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology, as well as a strategic collaboration with IQVIA Holdings Inc. to provide safety systems and services. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
ARGX Company Deck
ARGX Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a strongly positive commercial and financial picture: exceptional revenue growth (+90% YoY), first full-year operating profitability, a robust cash position (+>$1B YoY), and an expanding patient base (≈19,000). Clinically, the positive Phase III ADAPT OCULUS ocular MG readout (p=0.012; mean improvement 4.04 vs 1.99) and recent seronegative data (with a PDUFA in May) materially expand VYVGART’s addressable market and support label expansion. The company also highlighted a deepening pipeline and strategic investments in next-generation FcRn assets. Offsetting factors include a low gross margin (~11%), significant OpEx and R&D spend (combined R&D+SG&A $2.7B; ~30% YoY increase), a failed ALS study that halts that program, regulatory requests increasing trial burden in Graves, and payer/timing uncertainties that could delay realization of some label expansion benefits. Overall, the positive commercial momentum, profitability milestone, and major clinical win for ocular MG outweigh the challenges and near-term risks.View all ARGX earnings summariesARGX Stock 12 Month Forecast
Average Price Target
$1,039.72
▲(38.87% Upside)
Technical Analysis
Ownership Overview
―
Insiders
15.28% Mutual Funds
6.02% Other Institutional Investors
77.46% Public Companies and Individual Investors